Organogenesis (ORGO) Competitors

$2.59 -0.11 (-4.07%)

Closing price 05/14/2026 04:00 PM Eastern

Extended Trading

$2.60 +0.01 (+0.19%)

As of 05/14/2026 06:56 PM Eastern

ORGO vs. MPLT, CRVS, GHRS, OLMA, and QURE

Should you buy Organogenesis stock or one of its competitors? MarketBeat compares Organogenesis with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Organogenesis include Maplight Therapeutics (MPLT), Corvus Pharmaceuticals (CRVS), GH Research (GHRS), Olema Pharmaceuticals (OLMA), and uniQure (QURE). These companies are all part of the "pharmaceutical products" industry.

How does Organogenesis compare to Maplight Therapeutics?

Organogenesis (NASDAQ:ORGO) and Maplight Therapeutics (NASDAQ:MPLT) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, risk, media sentiment, valuation, dividends, profitability, analyst recommendations and institutional ownership.

49.6% of Organogenesis shares are owned by institutional investors. 33.0% of Organogenesis shares are owned by company insiders. Comparatively, 3.8% of Maplight Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Maplight Therapeutics had 13 more articles in the media than Organogenesis. MarketBeat recorded 20 mentions for Maplight Therapeutics and 7 mentions for Organogenesis. Maplight Therapeutics' average media sentiment score of 0.13 beat Organogenesis' score of -0.40 indicating that Maplight Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Organogenesis	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
Maplight Therapeutics	1 Very Positive mention(s)	9 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Organogenesis currently has a consensus price target of $8.50, indicating a potential upside of 228.19%. Maplight Therapeutics has a consensus price target of $34.43, indicating a potential upside of 17.54%. Given Organogenesis' higher probable upside, analysts clearly believe Organogenesis is more favorable than Maplight Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organogenesis	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Maplight Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

Organogenesis has higher revenue and earnings than Maplight Therapeutics. Organogenesis is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organogenesis	$564.17M	0.59	$37.03M	-$0.19	N/A
Maplight Therapeutics	N/A	N/A	-$161.15M	-$39.65	N/A

Maplight Therapeutics has a net margin of 0.00% compared to Organogenesis' net margin of -0.84%. Organogenesis' return on equity of 9.63% beat Maplight Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organogenesis	-0.84%	9.63%	4.76%
Maplight Therapeutics	N/A	N/A	N/A

Summary

Organogenesis beats Maplight Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Organogenesis compare to Corvus Pharmaceuticals?

Corvus Pharmaceuticals (NASDAQ:CRVS) and Organogenesis (NASDAQ:ORGO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, media sentiment, earnings, analyst recommendations, valuation and profitability.

Organogenesis has higher revenue and earnings than Corvus Pharmaceuticals. Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Organogenesis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corvus Pharmaceuticals	N/A	N/A	-$15.28M	-$0.52	N/A
Organogenesis	$564.17M	0.59	$37.03M	-$0.19	N/A

In the previous week, Corvus Pharmaceuticals had 1 more articles in the media than Organogenesis. MarketBeat recorded 8 mentions for Corvus Pharmaceuticals and 7 mentions for Organogenesis. Corvus Pharmaceuticals' average media sentiment score of -0.31 beat Organogenesis' score of -0.40 indicating that Corvus Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Corvus Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral
Organogenesis	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

46.6% of Corvus Pharmaceuticals shares are held by institutional investors. Comparatively, 49.6% of Organogenesis shares are held by institutional investors. 19.7% of Corvus Pharmaceuticals shares are held by insiders. Comparatively, 33.0% of Organogenesis shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Corvus Pharmaceuticals currently has a consensus price target of $33.33, indicating a potential upside of 144.20%. Organogenesis has a consensus price target of $8.50, indicating a potential upside of 228.19%. Given Organogenesis' higher probable upside, analysts plainly believe Organogenesis is more favorable than Corvus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corvus Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Organogenesis	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Corvus Pharmaceuticals has a beta of 0.94, meaning that its share price is 6% less volatile than the broader market. Comparatively, Organogenesis has a beta of 1.31, meaning that its share price is 31% more volatile than the broader market.

Corvus Pharmaceuticals has a net margin of 0.00% compared to Organogenesis' net margin of -0.84%. Organogenesis' return on equity of 9.63% beat Corvus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corvus Pharmaceuticals	N/A	-38.92%	-35.75%
Organogenesis	-0.84%	9.63%	4.76%

Summary

Organogenesis beats Corvus Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does Organogenesis compare to GH Research?

GH Research (NASDAQ:GHRS) and Organogenesis (NASDAQ:ORGO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, media sentiment, earnings, analyst recommendations, profitability and risk.

Organogenesis has higher revenue and earnings than GH Research. GH Research is trading at a lower price-to-earnings ratio than Organogenesis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GH Research	N/A	N/A	-$48.26M	-$0.80	N/A
Organogenesis	$564.17M	0.59	$37.03M	-$0.19	N/A

In the previous week, Organogenesis had 3 more articles in the media than GH Research. MarketBeat recorded 7 mentions for Organogenesis and 4 mentions for GH Research. GH Research's average media sentiment score of 1.89 beat Organogenesis' score of -0.40 indicating that GH Research is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GH Research	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Organogenesis	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

GH Research has a beta of 1.27, meaning that its stock price is 27% more volatile than the broader market. Comparatively, Organogenesis has a beta of 1.31, meaning that its stock price is 31% more volatile than the broader market.

GH Research presently has a consensus price target of $40.13, indicating a potential upside of 80.66%. Organogenesis has a consensus price target of $8.50, indicating a potential upside of 228.19%. Given Organogenesis' higher possible upside, analysts clearly believe Organogenesis is more favorable than GH Research.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GH Research	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Organogenesis	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

56.9% of GH Research shares are held by institutional investors. Comparatively, 49.6% of Organogenesis shares are held by institutional investors. 41.6% of GH Research shares are held by insiders. Comparatively, 33.0% of Organogenesis shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

GH Research has a net margin of 0.00% compared to Organogenesis' net margin of -0.84%. Organogenesis' return on equity of 9.63% beat GH Research's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GH Research	N/A	-16.30%	-15.77%
Organogenesis	-0.84%	9.63%	4.76%

Summary

Organogenesis beats GH Research on 9 of the 15 factors compared between the two stocks.

How does Organogenesis compare to Olema Pharmaceuticals?

Olema Pharmaceuticals (NASDAQ:OLMA) and Organogenesis (NASDAQ:ORGO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, media sentiment, earnings, analyst recommendations, profitability and risk.

Olema Pharmaceuticals presently has a consensus price target of $44.10, indicating a potential upside of 219.10%. Organogenesis has a consensus price target of $8.50, indicating a potential upside of 228.19%. Given Organogenesis' higher possible upside, analysts clearly believe Organogenesis is more favorable than Olema Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Olema Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
Organogenesis	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Olema Pharmaceuticals has a net margin of 0.00% compared to Organogenesis' net margin of -0.84%. Organogenesis' return on equity of 9.63% beat Olema Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Olema Pharmaceuticals	N/A	-46.00%	-41.22%
Organogenesis	-0.84%	9.63%	4.76%

91.8% of Olema Pharmaceuticals shares are held by institutional investors. Comparatively, 49.6% of Organogenesis shares are held by institutional investors. 12.6% of Olema Pharmaceuticals shares are held by insiders. Comparatively, 33.0% of Organogenesis shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Organogenesis has higher revenue and earnings than Olema Pharmaceuticals. Organogenesis is trading at a lower price-to-earnings ratio than Olema Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Olema Pharmaceuticals	N/A	N/A	-$162.45M	-$2.02	N/A
Organogenesis	$564.17M	0.59	$37.03M	-$0.19	N/A

In the previous week, Olema Pharmaceuticals had 7 more articles in the media than Organogenesis. MarketBeat recorded 14 mentions for Olema Pharmaceuticals and 7 mentions for Organogenesis. Olema Pharmaceuticals' average media sentiment score of 0.38 beat Organogenesis' score of -0.40 indicating that Olema Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Olema Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Organogenesis	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

Olema Pharmaceuticals has a beta of 2.05, meaning that its stock price is 105% more volatile than the broader market. Comparatively, Organogenesis has a beta of 1.31, meaning that its stock price is 31% more volatile than the broader market.

Summary

Olema Pharmaceuticals beats Organogenesis on 8 of the 15 factors compared between the two stocks.

How does Organogenesis compare to uniQure?

Organogenesis (NASDAQ:ORGO) and uniQure (NASDAQ:QURE) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, dividends, analyst recommendations, earnings, risk, profitability and valuation.

Organogenesis presently has a consensus price target of $8.50, indicating a potential upside of 228.19%. uniQure has a consensus price target of $42.83, indicating a potential upside of 54.35%. Given Organogenesis' higher probable upside, equities research analysts clearly believe Organogenesis is more favorable than uniQure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organogenesis	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
uniQure	1 Sell rating(s)	6 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.53

Organogenesis has a net margin of -0.84% compared to uniQure's net margin of -1,154.42%. Organogenesis' return on equity of 9.63% beat uniQure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organogenesis	-0.84%	9.63%	4.76%
uniQure	-1,154.42%	-145.81%	-27.15%

49.6% of Organogenesis shares are owned by institutional investors. Comparatively, 78.8% of uniQure shares are owned by institutional investors. 33.0% of Organogenesis shares are owned by company insiders. Comparatively, 4.8% of uniQure shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Organogenesis has higher revenue and earnings than uniQure. Organogenesis is trading at a lower price-to-earnings ratio than uniQure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organogenesis	$564.17M	0.59	$37.03M	-$0.19	N/A
uniQure	$16.10M	108.71	-$198.97M	-$3.48	N/A

In the previous week, uniQure had 7 more articles in the media than Organogenesis. MarketBeat recorded 14 mentions for uniQure and 7 mentions for Organogenesis. uniQure's average media sentiment score of 0.52 beat Organogenesis' score of -0.40 indicating that uniQure is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Organogenesis	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
uniQure	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Organogenesis has a beta of 1.31, indicating that its share price is 31% more volatile than the broader market. Comparatively, uniQure has a beta of 0.87, indicating that its share price is 13% less volatile than the broader market.

Summary

Organogenesis beats uniQure on 9 of the 16 factors compared between the two stocks.

Get Organogenesis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ORGO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ORGO vs. The Competition

Export

Metric	Organogenesis	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$347.42M	$3.06B	$6.34B	$12.37B
Dividend Yield	N/A	1.96%	2.80%	5.35%
P/E Ratio	-13.63	18.70	20.66	25.63
Price / Sales	0.59	271.92	549.87	76.59
Price / Cash	4.17	57.78	43.26	56.33
Price / Book	1.36	4.42	9.93	6.97
Net Income	$37.03M	$72.19M	$3.55B	$333.62M
7 Day Performance	9.28%	-0.43%	1.71%	1.09%
1 Month Performance	-0.38%	-0.96%	0.49%	3.08%
1 Year Performance	-14.52%	45.81%	39.41%	35.68%

Organogenesis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ORGO Organogenesis	2.1885 of 5 stars	$2.59 -4.1%	$8.50 +228.2%	-14.0%	$347.42M	$564.17M	N/A	950	High Trading Volume
MPLT Maplight Therapeutics	2.2541 of 5 stars	$28.61 -6.8%	$34.43 +20.3%	N/A	$1.30B	N/A	N/A	109	Earnings Report
CRVS Corvus Pharmaceuticals	2.0223 of 5 stars	$16.02 +3.6%	$33.33 +108.1%	+277.1%	$1.30B	N/A	N/A	30
GHRS GH Research	3.8221 of 5 stars	$21.69 +4.7%	$40.13 +85.0%	+122.5%	$1.28B	N/A	N/A	10	News Coverage Earnings Report
OLMA Olema Pharmaceuticals	2.2731 of 5 stars	$14.63 +2.2%	$44.40 +203.5%	+207.1%	$1.25B	N/A	N/A	70	Earnings Report Analyst Forecast Analyst Revision Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ORGO) was last updated on 5/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Organogenesis (ORGO) Competitors

ORGO vs. MPLT, CRVS, GHRS, OLMA, and QURE

How does Organogenesis compare to Maplight Therapeutics?

Summary

How does Organogenesis compare to Corvus Pharmaceuticals?

Summary

How does Organogenesis compare to GH Research?

Summary

How does Organogenesis compare to Olema Pharmaceuticals?

Summary

How does Organogenesis compare to uniQure?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORGO vs. The Competition

Organogenesis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Organogenesis (ORGO) Competitors

ORGO vs. MPLT, CRVS, GHRS, OLMA, and QURE

How does Organogenesis compare to Maplight Therapeutics?

Do institutionals & insiders believe in ORGO or MPLT?

Does the media prefer ORGO or MPLT?

Do analysts prefer ORGO or MPLT?

Which has stronger valuation and earnings, ORGO or MPLT?

Is ORGO or MPLT more profitable?

Summary

How does Organogenesis compare to Corvus Pharmaceuticals?

Which has preferable earnings & valuation, CRVS or ORGO?

Does the media favor CRVS or ORGO?

Do insiders and institutionals believe in CRVS or ORGO?

Do analysts recommend CRVS or ORGO?

Which has more volatility & risk, CRVS or ORGO?

Is CRVS or ORGO more profitable?

Summary

How does Organogenesis compare to GH Research?

Which has better earnings and valuation, GHRS or ORGO?

Does the media favor GHRS or ORGO?

Which has more risk & volatility, GHRS or ORGO?

Do analysts recommend GHRS or ORGO?

Do institutionals and insiders believe in GHRS or ORGO?

Is GHRS or ORGO more profitable?

Summary

How does Organogenesis compare to Olema Pharmaceuticals?

Do analysts recommend OLMA or ORGO?

Is OLMA or ORGO more profitable?

Do institutionals and insiders believe in OLMA or ORGO?

Which has better earnings and valuation, OLMA or ORGO?

Does the media favor OLMA or ORGO?

Which has more risk & volatility, OLMA or ORGO?

Summary

How does Organogenesis compare to uniQure?

Do analysts prefer ORGO or QURE?

Is ORGO or QURE more profitable?

Do insiders & institutionals have more ownership in ORGO or QURE?

Which has preferable valuation & earnings, ORGO or QURE?

Does the media refer more to ORGO or QURE?

Which has more volatility and risk, ORGO or QURE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORGO vs. The Competition

Organogenesis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools